LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the ...
On Tuesday, LAVA Therapeutics N.V. (NASDAQ:LVTX) initiated a process to review strategic options. The company implemented cost curtailment, including a workforce reduction, and has retained a ...
Investors are always looking for stocks that are poised to beat at earnings season and LAVA Therapeutics N.V. LVTX, may be one such company. The firm has earnings coming up pretty soon, and events are ...
Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory ...
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (LVTX) (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its ...
The latest price target for LAVA Therapeutics (NASDAQ:LVTX) was reported by JMP Securities on May 15, 2025. The analyst firm set a price target for $0.00 expecting LVTX to fall to within 12 months (a ...
T-cell engagers remain a hot therapeutic target for Big Pharma, and, now, Seagen is the latest drugmaker that wants in on the action, inking a deal with Lava Therapeutics. Seattle-based Seagen will ...
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody ® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the ...
LAVA Therapeutics, a Dutch Phase 1/2a biotech developing gamma-delta T cell therapies for cancer, announced terms for its IPO on Thursday. The Utrecht, Netherlands-based company plans to raise $101 ...
LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs
UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, ...
UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results